Another 89 ACOs join federal cost-sharing programs

Luke Gale | | Health Exec | Policy & Regulations
merger, acquisition, money, handshake - 113.76 Kb
Eighty-nine new accountable care organizations (ACOs) serving 1.2 million Medicare patients in 40 states and Washington, D.C. officially entered into agreements with the Centers for Medicare & Medicaid Services (CMS) as of July 1.

The new group joins 65 other healthcare organizations participating in the Medicare Shared Savings Program and similar cost-sharing initiatives, bringing the total number of ACOs to 154 and the total number of patients served by ACOs to more than 2.4 million, according to a July 9 CMS statement.

Accountable care organizations (ACOs) now stretch across 45 U.S. states and Washington, D.C., according to a white paper from Leavitt Partners. The 221 identified ACOs represent a 38 percent increase compared with those identified just six months ago.

A June whitepaper from Leavitt Partners, “Growth and Dispersion of Accountable Care Organizations,” reported 221 ACOs across 45 states and Washington, D.C. That figure represents a 38 percent increase compared with the ACOs identified six months earlier. The paper also said that ACO activity in the private sector outnumbers the government sector by a factor of four to one, while the majority of ACOs are found in larger metropolitan regions.

Luke Gale

Related Content

Report: UnitedHealth under investigation by DOJ for Medicare Advantage upcoding
FDA approves first therapy for very rare lipid storage disorder
FDA announces Class I recall of Boston Scientific pacemakers—replacement may be necessary
FDA ends semaglutide shortage, closing the door on compounded Wegovy, Ozempic
American Heart Association highlights importance of NIH as battle over Trump funding cuts continues
Federal judge sides with FTC; case against PBMs to move forward

Around the web

Cardiovascular Business
American Heart Association highlights importance of NIH as battle over Trump funding cuts continues

“Now more than ever, we must recognize that our country’s leadership in groundbreaking medical research spurs scientific innovation, improves public health and creates new innovations that save and improve lives nationwide,” Joseph C. Wu, MD, PhD, explained in a statement. 

Cardiovascular Business
Cardiologist questions FDA’s approval process for high-risk medical devices

The technology used to diagnose, treat and manage cardiovascular disease is always evolving, keeping FDA officials quite busy. But have the agency's standards been slipping in recent years? A cardiologist with Cedars-Sinai Medical Center explored that very question.

Cardiovascular Business
FDA announces new recall of Johnson & Johnson heart pumps over safety concerns

No devices need to be returned at this time. However, the FDA warned, using these heart pumps without reviewing the updated instructions could result in "serious injury or death.”